

Bariatric Surgery on Type 2 Diabetes Mellitus Patients in Japan

Junichiro MORI^{1)*}, Yoshihiko SATO²⁾
Hiroaki ISHII²⁾ and Mitsuhsisa KOMATSU²⁾

1) *Center for Medical Education, Shinshu University School of Medicine*

2) *Department of Aging Medicine and Geriatrics, Shinshu University Graduate School of Medicine*

Key words : bariatric surgery, obesity, diabetes

I Introduction

Amidst a worldwide epidemic of diabetes, the World Health Organization estimates that more than 220 million people have diabetes and an estimated 3.4 million people died from consequences of high blood sugar in 2004¹⁾. In Japan, a 2009 report from the Ministry of Health, Labour and Welfare stated that there are approximately 8.9 million Japanese who are strongly suspected of having diabetes²⁾. Over time, diabetes can damage the heart, blood vessels, eyes, kidneys, and nerves. In particular, diabetes increases the risk of heart disease and stroke.

Obesity carries with it significant risks of diabetes³⁾. Improvement in obesity is attendant with improvements in this ailment⁴⁾⁵⁾, and obese people consequently have been treated through pharmacotherapy, and intervention in life habits, including diet and exercise. Even with such treatment, however, it is very difficult to achieve satisfactory body weight loss. In the last few years many studies have been performed to compare intensive glucose control therapy with standard therapy. Most of the results show that body weight did not change with either intensive glucose control therapy or standard therapy⁶⁾⁷⁾. Additionally, in the case of the Veterans Affairs Diabetes Trial (VADT), body mass index (BMI) of the patients increased from 31.3 kg/m² to 33.8 kg/m² with intensive glucose control therapy in

a median follow-up period of 5.6 years⁸⁾. Moreover, many patients who are initially successful at weight loss then go on to rebound⁹⁾. Thus, promoting weight loss without rebound is a major issue in treatment, especially in severely obese patients. Recently, there has been an increase in patients with a BMI > 35 undergoing bariatric surgery⁹⁾. Bariatric surgery generally consists of either gastric bypass, as typified by the Roux-en-Y Gastric Bypass (RYGB), or gastric binding, including vertical banded gastroplasty and laparoscopic adjustable gastric banding. The RYGB method creates a proximal pouch by segmentation of the stomach and the proximal pouch is drained with a Roux limb of proximal jejunum¹⁰⁾. Vertical banded gastroplasty features a small pouch based on the lesser curvature of the stomach and a mesh or plastic band around the outlet of the pouch to narrow the outlet to about 1 cm¹⁰⁾. Laparoscopic adjustable gastric banding is similar to vertical banding but uses an adjustable band, which is lined with an inflatable cuff joined to a small reservoir to allow adjustment of the pouch outflow and meal capacity¹⁰⁾. There has been a notable increase in studies describing the effect of bariatric surgery on type 2 diabetes patients⁹⁾.

II Effect of Bariatric Surgery on Obesity and Diabetes

Although an average of 55.9 % loss in excess body weight was observed in bariatric surgery⁹⁾, the extent of operation-induced weight loss varies depending on the surgical method¹¹⁾. Gastric binding reduce the storage capacity of the stomach and as a result early satiety arises, leading to a decreased

* Corresponding author : Junichiro Mori
Center for Medical Education, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto-city, Nagano-prefecture 390-8621, Japan

Table 1 Efficacy for improvement in diabetes-related outcomes for diabetic and glucose-intolerant patients¹⁶⁾

	Total (n)	Gastric Binding (n)	Gastric Bypass (n)
Absolute Weight Loss (Kg)	-41.9 (266)	-26.0 (56)	-50.54 (129)
BMI Decrease (kg/m ²)	-14.0 (306)	-9.1 (56)	-18.0 (166)
Excess Loss (%)	-57.3 (267)	-41.0 (83)	-65.7 (184)
Fasting Insulin (pmol/L)	-123.9 (160)	-49.5 (56)	-153.7 (90)
HbA1c (%)	-2.4 (171)	-1.2 (83)	-3.0 (88)
Fasting Glucose (mmol/L)	-4.0 (296)	-3.2 (56)	-3.4 (164)

BMI: body mass index

caloric intake¹²⁾. RYGB also has this aspect but in addition it shortens the functional length of the small intestine and creates a short-bowel syndrome¹³⁾. While loss in body weight from intervention in life habits is insufficient³⁾¹⁴⁾¹⁵⁾, it was 46.2 % for gastric binding and 59.5 % for gastric bypass, respectively, thus showing that bariatric surgery leads to more efficient weight-loss results⁹⁾. However, although bariatric surgery generally leads to a great improvement in diabetes¹⁶⁾ (Table 1), there is a gradation of results depending on the procedure¹⁷⁾. Additionally for type 2 diabetes patients, studies on gastric bypass have shown that improvements in fasting plasma glucose and insulin sensitivity are evident prior to weight loss³⁾¹⁸⁾¹⁹⁾. These kinds of changes are not observed in gastric binding⁹⁾²⁰⁾. From these results, apart from improvements in insulin sensitivity induced through weight loss, gastric bypass is also thought to improve glucose metabolism.

III Effects of Bariatric Surgery on Intestinal Hormones

One hypothesis to explain this phenomenon is the influence of gastrointestinal hormones. Glucagon-like peptide-1 (GLP-1), an intestinal hormone secreted from the distal ileum and colon in response to nutrient ingestion¹⁷⁾, increases c-AMP in pancreatic β -cells and is involved in glucose-dependent insulin release²⁰⁾²¹⁾. GLP-1 decreases dietary intake by slowing gastric emptying⁹⁾²²⁾, controlling secretion of gastric acid²³⁾ and glucagon²⁴⁾, and inducing satiety by working on the central nervous system^{25)–27)}.

GLP-1 is also involved in the proliferation and regeneration of pancreatic β -cells²⁸⁾²⁹⁾. There have been numerous studies detailing a post-operative increase in GLP-1 secretion from gastric bypass, and this increase occurs prior to post-gastric bypass weight loss^{30)–33)}. Studies show that the post-gastric bypass GLP-1 level is significantly higher when compared to the post-gastric binding GLP-1 level³⁴⁾³⁵⁾. There are also studies showing that the GLP-1 level is significantly higher in post-gastric bypass groups than in groups reducing their weight through diet and/or medication³⁶⁾³⁷⁾. Because there is no statistical difference in post-operative body weight based on surgical methods according to these studies, it seems that the change in body weight is not the primary factor modulating GLP-1 in gastric bypass. Based on the food stimulation-induced secretion from the distal ileum, some groups think that increases in GLP-1 secretion after the gastric bypass can be attributed to the phenomenon whereby the post-operative gut forms in such a way that dense foods pass rapidly into the distal intestine^{37)–40)}. As no improvement occurs in fasting plasma glucose in cases in which food is made to pass via both the duodenum and the stomach-small intestine shunt, an alternative hypothesis is that food passing via the proximal intestine exerts a negative influence on glucose metabolism⁴¹⁾⁴²⁾. When considering the effect of GLP-1, it is possible that the increase in endogenous GLP-1 secretion plays an important role in the improvement of glucose metabolism by the gastric bypass surgery.

Although ghrelin is similar to GLP-1 in that it is

Table 2 Complications from bariatric surgery⁵⁹⁾

	RYGB (Studies/Patients)	VBG (Studies/Patients)	AGB (Studies/Patients)
% Early or time-unspecified mortality Rate	1.0 (15/907)	0.2 (11/401)	0.4 (6/268)
GI Symptoms			
% All	16.9 (34/7374)	17.5 (21/1692)	7.0 (17/3400)
% Reflux	10.9 (3/727)	2.2 (7/823)	4.7 (4/485)
% Vomiting	15.7 (8/1324)	18.4 (10/1177)	2.5 (4/562)
% Nutritional and electrolyte abnormalities	16.9 (10/2088)	2.5 (4/397)	NR
% Anatomic or Stromal Stenosis	4.6 (30/5645)	6.0 (14/1456)	NR
% Bleeding	2.0 (19/5026)	0.7 (6/1027)	0.3 (6/2844)
% Reoperation	1.6 (9/4356)	11.3 (7/520)	7.7 (11/2140)

RYGB: Roux-en-Y Gastric Bypass, VBG: Vertical Banded Gastroplasty, AGB: Adjustable Gastric Band, NR: not reported

related to the appetite, it is actually an appetite-stimulating hormone⁴³⁾⁻⁴⁵⁾. It is likely that the appetite stimulation from ghrelin is due to its increasing activity in the stomach⁴⁴⁾⁴⁶⁾ and suppression of insulin secretion⁴⁶⁾. Ghrelin levels increase in dietary restriction-induced weight loss and when there is a negative energy balance⁴⁷⁾, and conversely, decrease when eating or in the case of the obese⁴⁸⁾. However in the case of the obese, ghrelin levels become unchanged even when eating, and therefore, ghrelin level is a potential factor in obesity⁴⁹⁾. There are many reports of postprandial, post-RYGB ghrelin levels and ghrelin levels decreasing in times of fasting compared to pre-operation⁵⁰⁾⁵¹⁾, lean⁵¹⁾⁵²⁾, normal body weight⁵³⁾⁵⁴⁾, obese⁵¹⁾⁻⁵⁵⁾, and post-surgery in other types of bariatric surgery³⁵⁾⁵⁴⁾⁵⁶⁾. However, there are also studies showing that postprandial, post-RYGB ghrelin levels are comparable to those of lean and post-surgery patients in other kinds of bariatric surgery⁵⁷⁾⁵⁸⁾. It has been reported that a decrease in ghrelin levels occurs immediately following surgery and lasts for more than a year⁵⁴⁾⁵⁸⁾. Through RYGB, food bypasses the distal stomach in which ghrelin is released, and this may account for the post-bypass decrease in ghrelin levels⁵⁰⁾. This explanation would suggest the possibility that appetite cannot be suppressed in bariatric surgery that does not bypass the distal stomach.

IV Adverse Effects of Bariatric Surgery

There are some complications from bariatric surgery that occur solely from its nature as surgery. In addition to the post-operative short-term mortality rates (deaths within 30 days post-surgery) of 0.2 % in the case of VBG and 1.0 % in the case of the potentially more effective RYGB⁵⁹⁾, complications other than death have been reported as follows: GI symptoms in 16.9 % of RYGB cases and 17.5 % of VBG cases, and nutritional and electrolyte abnormalities in 16.9 % for RYGB and 2.5 % for VBG (Table 2)⁵⁹⁾.

V Clinical Application of Bariatric Surgery in Japan

As previously stated, there are reports that bariatric surgery leads to dramatic improvement in type 2 diabetes compared to pharmacotherapy and lifestyle intervention-based treatment. Will bariatric surgery replace conventional medication and/or life style intervention-based treatment in Japan? At present, however, most of these reports are not necessarily targeting regular subjects, given the subjects' extremely high average BMI of 47.9 kg/m² and relatively young average age of 40.2 years old.

Obesity in the Japanese population is much less than in Western populations. The Ministry of Health, Labour and Welfare, Japan reported that

only 3.7 % of the population is obese (BMI > 30)⁶⁰. The rate of obesity in diabetes is reported to be similar to that in the rest of the Japanese population⁶¹, and at present bariatric surgery has only a limited application in Japan.

VI Summary

In this review, we outlined the endocrinological and clinical effects of bariatric surgery in obese and diabetic patients. Recently, in certain countries, there has been an increase in obese patients undergoing bariatric surgery which leads to more efficient

weight-loss results. Bariatric surgery is an effective treatment option for severely obese patients for whom weight loss has been problematic with conventional pharmacotherapy and/or life style intervention-based treatment. At present, however, there is a need for a high-evidence level cohort study based on previous research that varies by age and obesity level in order to further the discussion on whether bariatric surgery should be given precedence over conventional medication and life style intervention-based treatment in Japan.

References

- 1) World Health Organization : Diabetes. Fact sheet No312, Geneva, 2011
- 2) Ministry of Health, Labour and Welfare, Japan : National Health and Nutrition examination 2009. Tokyo, 2010
- 3) Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS : Prevalence of obesity diabetes and obesity-related health risk factors 2001. *JAMA* 289 : 76-79, 2003
- 4) Pi-Sunyer X, Blackburn G, Brancati FL, Bray GA, Bright R, Clark JM, Curtis JM, Espeland MA, Foreyt JP, Graves K, Haffner SM, Harrison B, Hill JO, Horton ES, Jakicic J, Jeffery RW, Johnson KC, Kahn S, Kelley DE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ, Montgomery B, Nathan DM, Patricio J, Peters A, Redmon JB, Reeves RS, Ryan DH, Safford M, Van Dorsten B, Wadden TA, Wagenknecht L, Wesche-Thobaben J, Wing RR, Yonovski SZ : Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes : one-year results of the look AHEAD trial. *Diabetes Care* 30 : 1374-1383, 2007
- 5) Espeland MA, Bray GA, Neiberg R, Rejeski WJ, Knowler WC, Lang W, Cheskin LD, Williamson D, Lewis CB, Wing R : Describing patterns of weight changes using principal components analysis : results from the Action for Health in Diabetes (Look AHEAD) research group. *Ann Epidemiol* 19 : 701-710, 2009
- 6) Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompont S, de Galan BE, Joshi R, Travert F : Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med* 358 : 2560-2572, 2008
- 7) Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr, Probstfield JL, Cushman WC, Ginsberg HN, Bigger JT, Grimm RH Jr, Byington RP, Rosenberg YD, Friedewald WT : Long-term effects of intensive glucose lowering on cardiovascular outcomes. *N Engl J Med* 364 : 818-828, 2011
- 8) Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD : Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med* 360 : 129-139, 2009
- 9) Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, Bantle JP, Sledge I : Weight and type 2 diabetes after bariatric surgery : systematic review and meta-analysis. *Am J Med* 122 : 248-256, 2009
- 10) Pories WJ : Bariatric surgery : risks and rewards : *J Clin Endocrinol Metab* 93 : S89-S96, 2008
- 11) Garb J, Welch G, Zagarins S, Kuhn J, Romanelli J : Bariatric surgery for the treatment of morbid obesity : a meta-analysis of weight loss outcomes for laparoscopic adjustable gastric banding and laparoscopic gastric bypass. *Obes Surg* 19 : 1447-1455, 2009
- 12) Schneider BE, Mun EC : Surgical management of morbid obesity. *Diabetes Care* 28 : 475-480, 2005

- 13) Santry HP, Gillen DL, Lauderdale DS : Trends in bariatric surgical procedures. *JAMA* 19 : 1909-1917, 2005
- 14) Sjöström CD, Peltonen M, Wede H, Sjöström L : Differentiated long-term effects of intentional weight loss on diabetes and hypertension. *Hypertension* 36 : 20-25, 2000
- 15) Knowler WC, Barrett-Connor E, Fowler SE, Hamman F, Lachin JM, Walker EA, Nathan DM : Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 346 : 393-403, 2002
- 16) Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories K, Fahrenbach K, Schoelles K : Bariatric surgery : a systematic review and meta-analysis. *JAMA* 292 : 1724-1737, 2004
- 17) Pournaras DJ, LeRoux CW : The effect of bariatric surgery on gut hormones that alter appetite. *Diabetes Metab* 35 : 508-512, 2009
- 18) Bose M, Teixeira J, Olivan B, Bawa B, Arias S, Machineni S, Pi-Sunyer FX, Scherer PE, Laferrère B : Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery. *J Diabetes* 2 : 47-55, 2009
- 19) Bikman BT, Zheng D, Pories WJ, Chapman W, Pender JR, Bowden RC, Reed MA, Cortright RN, Tapscott EB, Houmard JA, Tanner CJ, Lee J, Dohm GL : Mechanism for improved insulin sensitivity after gastric bypass surgery. *J Clin Endocrinol Metab* 93 : 4656-4663, 2008
- 20) Vincent RP, leRoux CW : Changes in gut hormones after bariatric surgery. *Clin Endocrinol* 69 : 173-179, 2008
- 21) Giorgino F, Natalicchio A, Leonardini A, Laviola L : Exploiting the pleiotropic actions of GLP-1 for the management of type 2 diabetes mellitus and its complication. *Diabetes Res Clin Pract* 78 : S59-S67, 2007
- 22) Edholm T, Degerblad M, Grybäck P, Hilsted L, Holst JJ, Jacobsson H, Efendic S, Schmidt PT, Hellström PM : Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite and insulin-glucose homeostasis. *Neurogastroenterol Motil* 22 : 1191-1200, 2010
- 23) Nauck MA, Niedereichholz U, Ettl R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH : Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. *Am J Physiol* 273 : E981-E988, 1997
- 24) Asmar M, Bache M, Knop FK, Madsbad S, Holst JJ : Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans ? *J Clin Endocrinol Metab* 95 : 2367-2375, 2010
- 25) Jayasena CN, Bloom SR : Role of gut hormones in obesity. *Endocrinol Metab Clin North Am* 37 : 769-787, 2008
- 26) Ma X, Bruning J, Ashcroft FM : Glucagon-like peptide 1 stimulates hypothalamic proopiomelanocortin neurons. *J Neurosci* 27 : 7125-7129, 2007
- 27) Pannacciulli N, Le DS, Salbe AD, Chen K, Reiman EM, Tataranni PA, Krakoff J : Postprandial glucagon-like peptide-1 (GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans. *Neuroimage* 35 : 511-517, 2007
- 28) Holst JJ : The physiology of glucagon-like peptide 1. *Physiol Rev* 87 : 1409-1439, 2007
- 29) Buteau J, Rduit R, Susini S, Prentki M : Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. *Diabetologia* 42 : 856-864, 1999
- 30) MacDonald PE, El-Kholy W, Riedel MJ, Salapatek AM, Light PE, Wheeler MB : The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. *Diabetes* 51 : S434-S442, 2002
- 31) Goldfine AB, Mun EC, Devine E, Bernier R, Baz-Hecht M, Jones DB, Schneider BE, Holst JJ, Patti ME : Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal. *J Clin Endocrinol Metab* 92 : 4678-4685, 2007
- 32) LeRoux CW, Aylwin SJ, Batterham RL, Borg CM, Coyle F, Prasad V, Shurey S, Ghatei MA, Patel AG, Bloom SR : Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve

- metabolic parameters. *Ann Surg* 243 : 108-114, 2006
- 33) Morinigo R, Moizé V, Musri M, Lacy AM, Navarro S, Marín JL, Delgado S, Casamitjana R, Vidal J : Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. *J Clin Endocrinol Metab* 91 : 1735-1740, 2006
 - 34) Korner J, Bessler M, Inabnet W, Taveras C, Holst JJ : Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. *Surg Obes Relat Dis* 3 : 597-601, 2007
 - 35) Rodieux F, Giusti V, D'Alessio DA, Suter M, Tappy L : Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release. *Obesity (Silver Spring)* 16 : 298-305, 2008
 - 36) Rubino F, Gagner M, Gentileschi P, Kini S, Fukuyama S, Feng J, Diamond E : The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. *Ann Surg* 240 : 236-242, 2004
 - 37) Rubino F, Forgione A, Cummings DE, Vix M, Gnuli D, Mingrone G, Castagneto M, Marescaux J : The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. *Ann Surg* 244 : 741-749, 2006
 - 38) Nguyen NT, Stevens CM, Wolfe BM : Incidence and outcome of anastomotic stricture after laparoscopic gastric bypass. *J Gastrointest Surg* 7 : 997-1003, 2003
 - 39) Suter M, Giusti V, Heraief E, Zysset F, Calmes JM : Laparoscopic Roux-en-Y gastric bypass : initial 2-year experience. *Surg Endosc* 17 : 603-609, 2003
 - 40) Cooney RN, Haluck RS, Ku J, Bass T, MacLeod J, Brunner H, Miller CA : Analysis of cost outliers after gastric bypass surgery : what can we learn? *Obes Surg* 13 : 29-36, 2003
 - 41) Rubino F : Is type 2 diabetes an operable intestinal disease? A provocative yet reasonable hypothesis. *Diabetes Care* 31 : S290-S296, 2008
 - 42) Colquitt J, Clegg A, Sidhu M, Royle P : Surgery for morbid obesity. *Cochrane Database Syst Rev* : CD003641, 2003
 - 43) Murphy KG, Bloom SR : Gut hormones and the regulation of energy homeostasis. *Nature* 444 : 854-859, 2006
 - 44) Cummings DE, Overduin J : Gastrointestinal regulation of food intake. *J Clin Invest* 117 : 13-23, 2007
 - 45) Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, Matsukura S : A role for ghrelin in the central regulation of feeding. *Nature* 409 : 194-198, 2001
 - 46) Zwirski-Korczała K, Konturek SJ, Sadowski M, Wylezol M, Kuka D, Sowa P, Adamczyk-Sowa M, Kukla MM, Berdowska A, Rehfeld JF, Bielanski W, Brzozowski T : Basal and postprandial plasma levels of PYY, ghrelin, cholecystokinin, gastrin and insulin in women with moderate and morbid obesity and metabolic syndrome. *J Physiol Pharmacol* 58 : 13-35, 2007
 - 47) Hansen TK, Dall R, Hosoda H, Kojima M, Kangawa K, Christiansen JS, Jorgensen JO : Weight loss increases circulating levels of ghrelin in human obesity. *Clin Endocrinol* 56 : 203-206, 2002
 - 48) Cummings DE, Foster-Schubert KE, Overduin J : Ghrelin and energy balance : focus on current controversies. *Curr Drug Targets* 6 : 153-169, 2005
 - 49) English PJ, Ghatei MA, Malik IA, Bloom SR, Wilding JP : Food fails to suppress ghrelin levels in obese humans. *J Clin Endocrinol Metab* 87 : 2984, 2002
 - 50) Lin E, Gletsu N, Fugate K, McClusky D, Gu LH, Zhu JL, Ramshaw BJ, Papanicolaou DA, Ziegler TR, Smith CD : The effects of gastric surgery on systemic ghrelin levels in the morbidly obese. *Arch Surg* 139 : 780-784, 2004
 - 51) Tritos NA, Mun E, Bertkau A, Grayson R, Maratos-Flier E, Goldfine A : Serum ghrelin levels in response to glucose load in obese subjects post-gastric bypass surgery. *Obes Res* 11 : 919-924, 2003
 - 52) Chan JL, Mun EC, Stoyneva V, Mantzoros CS, Goldfine AB : Peptide YY levels are elevated after gastric bypass surgery. *Obesity (Silver Spring)* 14 : 194-198, 2006

- 53) Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, Purnell JQ : Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. *N Engl J Med* 346 : 1623-1630, 2002
 - 54) Leonetti F, Silecchia G, Iacobellis G, Ribaldo MC, Zappaterreno A, Tiberti C, Iannucci CV, Perrotta N, Bacci V, Basso MS, Basso N, DiMario U : Different plasma ghrelin levels after laparoscopic gastric bypass and adjustable gastric banding in morbid obese subjects. *J Clin Endocrinol Metab* 88 : 4227-4231, 2003
 - 55) Engstrom BE, Ohrvall M, Sundbom M, Lind L, Karlsson FA : Meal suppression of circulating ghrelin is normalized in obese individuals following gastric bypass surgery. *Int J Obes* 31 : 476-780, 2007
 - 56) Korner J, Inabnet W, Conwell IM, Taveras C, Daud A, Olivero-Rivera L, Restuccia NL, Bessle M : Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels. *Obesity (Silver Spring)* 14 : 1553-1561, 2006
 - 57) Korner J, Bessler M, Cirilo LJ, Conwell IM, Daud A, Restuccia NL, Wardlaw SL : Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. *J Clin Endocrinol Metab* 90 : 359-365, 2005
 - 58) LeRoux CW, Welbourn R, Werling M, Osborne A, Kokkinos A, Laurenus A, Lönroth H, Fändriks L, Ghatei MA, Bloom SR, Olber T : Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. *Ann Surg* 246 : 780-785, 2007
 - 59) Maggard MA, Shugarman LR, Suttorp M, Maglione M, Sugeran HJ, Livingston EH, Nguyen NT, Li Z, Mojica WA, Hilton L, Rhodes S, Morton SC, Shekelle PG : Meta-analysis : surgical treatment of obesity. *Ann Intern Med* 142 : 547-559, 2005
 - 60) Ministry of Health, Labour and Welfare, Japan : Outline of the diabetes mellitus field study 2002. Tokyo, 2004
 - 61) Sone H, Mizuno S, Fujii H, Yoshimura Y, Yamasaki Y, Ishibashi S, Katayama S, Saito Y, Ito H, Ohashi Y, Akanuma Y, Yamada N : Is the diagnosis of metabolic syndrome useful for predicting cardiovascular disease in Asian diabetic patients ? Analysis from the Japan Diabetes Complications Study. *Diabetes Care* 28 : 1463-1471, 2005
- (2011. 1. 27 received ; 2011. 5. 2 accepted)
-